Ageruo

Ageruo is a UK-based biotechnology company dedicated to discovering and developing novel anti-infectives to combat the global threat of antimicrobial resistance (AMR). The company focuses on identifying and validating underexploited bacterial targets, particularly those essential for the survival of multi-drug resistant Gram-negative pathogens. By leveraging a lean, virtual operating model and deep expertise in infectious disease R&D, Ageruo aims to build a pipeline of first-in-class small molecule inhibitors. Their approach addresses critical gaps in the current antibiotic landscape, targeting high-priority pathogens identified by the World Health Organization. The leadership team consists of industry veterans with a proven track record in successful antibiotic development.